Expert Discusses Latest Nivolumab Data in Hodgkin Lymphoma

Danielle Bucco
Published: Thursday, Jun 15, 2017

Michelle A. Fanale, MD

Michelle A. Fanale, MD

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (BV; Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant (ASCT), according to the latest data from the phase II CheckMate-205 trial.

In the study, 77% of enrolled patients had stage III or higher disease. The overall response rate was 65% in BV-naïve patients, 68% in patients who received BV after ASCT, and 73% in patients who received BV before and/or after ASCT. The complete response (CR) rates were 29%, 13%, and 12%, respectively.

“We have found the dosing is quite manageable and this is generally the type of treatment that patients can continue being on for the rest of their lives,” said lead study author Michelle A. Fanale, MD.

In May 2016, the FDA granted nivolumab accelerated approval for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation BV, based on findings from the CheckMate-205 and CheckMate-039 trials.

In an interview with OncLive, Fanale, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the latest CheckMate-205 data and the next steps with nivolumab in Hodgkin lymphoma.

OncLive: Can you discuss the phase II study?

This was a phase II registrational trial of nivolumab for patients who have relapsed classical Hodgkin lymphoma or had already previously undergone ASCT. There were different cohorts of certain patients who had previously received BV, whereas other patients had not previously received BV.

How do these results impact the treatment landscape?

These results are very applicable for seeing patients and taking care of them on an everyday basis. Nivolumab was approved in the United States in May 2016 for the relapse/refractory patient population who have classical Hodgkin lymphoma or need a fourth-line of treatment. 

What was seen from this registrational trial, which is also similar to the pembrolizumab phase II trial, was that both of these drugs work well, even for patients who previously had been resistant to BV or had progressed after BV treatment.

What was seen across the board was that the drug works very well overall. It saw a 70% response rate and the CR rate ranged anywhere from 15% up to almost 30% for the patients who were BV naive.

What are the next steps following this research?

The next steps are to potentially look at nivolumab in combination with BV. There are a couple of updates being presented here at the meeting. There is the phase II second-line pre-ASCT and there is a data update that will be given by Dr Alex Herrera. There is also the ECOG trial, that looks at BV plus nivolumab as a doublet that includes patients who are third-line and greater.

There are 2 ongoing Hodgkin lymphoma trials looking at elderly patients. The first is an investigator initiated trial. Additionally, there is a separate sponsored clinical trial looking at this doublet for patients who otherwise wouldn’t have been good candidates for chemotherapy, either because of age or organ issues.

Is nivolumab being looked at in combination with any other regimens that you find exciting?

Nivolumab is also now potentially being looked at in combination with some HDAC inhibitors both in Hodgkin lymphoma and other lymphoma subtypes. What is very interesting with this drug is the fact that the PD-1 inhibitors have quite broad applicability. They were initially approved for solid tumors and now have gained traction, particularly for patients with classical Hodgkin lymphoma. They also hold a lot of applicability for B-cell non-Hodgkin lymphoma. Additionally, they are being looked at in T-cell lymphoma, too. 

What are some remaining challenges that you would like to see addressed?

In my opinion, one of the remaining challenges is similar to when BV was launched. We still don’t know what the ideal length of time the treatment should be. Is a partial response almost as good as a CR?

In this setting, you can see durations of remission for patients in partial remission almost approaching what you would see for durability with CR. I think it is important to understand what the level of response means and that we should always be driving for CR.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x